KFDA approved Yuyu new anti-osteoporosis drug, Maxmavil

Published: 2004-11-22 06:56:00

Updated: 2004-11-22 06:56:00

Yuyu announced to get the KFDA approval for Maxmavil, a new combined anti-osteoporosis drug formulated with Alrendronate and Calcitriol on Nov. 16 and therefore to launched its sales around coming March next year.

Yuyu has succeeded in the development of Maxmavil with 7 year R&D investment and...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK